In major news released today, ORIG3N announced that it has opened a new regenerative medicine laboratory and expanded headquarters in Boston.
Founded in 2014, ORIG3N is creating the world’s largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. It uses these blood cells to produce patient-specific iPSCs to grow different cell types, including heart cells (cardiomyocytes), liver cells (hepatocytes), brain cells (neurons), and more.
In addition to collecting donated blood samples for iPSC production, ORIG3N offers an optional LifeCapsule membership, in which individuals can pay $99/year to get permanent access to their own immortalized iPS cells. ORIG3N also has two other business units, LifeProfile and LifeSystems, which are discussed in detail in the interview below.
Learn more by reading the full press release below, printed with permission from Julie Hall, Managing Director of Havas Health and media contact for ORIG3N.
ORIG3N Opens Regenerative Medicine Laboratory and Expanded Headquarters In Boston’s Innovation District
Advancing the future of medicine by providing the world’s largest biorepository of iPS cells
Mayor Walsh Proclaims April 26th “Future of Medicine Day” for the City of Boston
BOSTON, April 26, 2016; 13:44 ET from ORIG3N, Inc. — ORIG3N, Inc, a pioneer in the field of regenerative medicine, today announced the formal opening of its new headquarters and laboratory in Boston’s Seaport District, at 27 Drydock Avenue within the Innovation and Design Building. ORIG3N’s new expanded facility will provide state-of-the-art functionality to sustain collaborative research programs that support ORIG3N’s cellular models called LifeSystems™, as well as the company’s product development and commercial activities.
Mayor Martin J. Walsh donated a blood sample for Boston-based ORIG3N, which is building the world’s largest crowdsourced biorepository of induced pluripotent stem cells, called LifeCapsule. A half teaspoon of donated blood can be grown into different cell types, including neurons, heart cells and liver cells.
Mayor Martin J. Walsh viewed the contents of ORIG3N’s LifeCapsule, the world’s largest biorepository of induced pluripotent stem cells (iPSCs), during a lab tour with Marcie Glicksman, VP of Biology at ORIG3N. ORIG3N is the only biotechnology company that is crowdsourcing blood samples to understand the cellular and molecular foundations of disease. ORIG3N’s new facility will help accelerate the next stage of evolution with iPSC technology.
Founded in 2014 by serial entrepreneurs Robin Y. Smith, CEO and Kate Blanchard, COO, ORIG3N uses iPSC technology to accelerate the future of medicine, including the pace of drug development, to overcome the trial-and-error approach common today. ORIG3N is the only biotechnology company that is crowdsourcing blood samples creating a new approach to the understanding and treatment of a variety of diseases.
ORIG3N builds and maintains the world’s largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. The new facility will help accelerate the next stage of evolution with iPSC technology.
“Regenerative medicine is at the same stage today as the Internet was in 1993. We are on the verge of seeing huge advances in this technology and as part of our mission we are making large and diverse patient cohorts available to researchers while at the same time educating patients on what this technology is,” said Smith, in addressing an audience that included government officials and representatives from the biotech and life sciences community. “Being in Boston enables our organization to bring our technology to the epicenter of biotech research in the US.”
“The foundation for the regenerative medicine revolution requires unhindered access to patient samples,” adds Blanchard. “LifeCapsule has grown exponentially by directly engaging with consumers and patients worldwide. The remarkable growth of LifeCapsule has given ORIG3N the unique ability to create a living snapshot of humanity.”
In attending the opening, Mayor Martin J. Walsh noted, “ORIG3N is a great fit for the Innovation District and our city’s biotechnology and life sciences community, and we are proud to welcome them to Boston. Their work in studying rare, genetically-inherited diseases will have a huge impact on the future of medicine. ORIG3N’s future is bright as they continue to expand and grow their partnerships, and we are excited that they see Boston as the best place to succeed.”
About ORIG3N, Inc.
ORIG3N is leading a transformation of the understanding and treatment of rare, genetically-inherited diseases. We’ve established the world’s largest crowdsourced cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity we call LifeCapsule. Thousands of people have already contributed to advancing the future of healthcare—and to safeguarding their own future health. The founders are serial entrepreneurs whose previous venture, ArtusLabs, was acquired by PerkinElmer in 2011.
For more information, visit www.orig3n.com.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.